Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
Viking Therapeutics, Inc. (VKTX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 07/26/2023 |
S-3ASR
| Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers: |
| 07/26/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/26/2023 |
8-K
| Quarterly results |
| 05/18/2023 |
4
| Rowland Charles A Jr (Director) has filed a Form 4 on Viking Therapeutics, Inc.|
Txns:
| Sold 40,000 shares
@ $25, valued at
$1M
Exercised 40,000 options to buy
@ $1.08, valued at
$43.2k
|
|
| 05/18/2023 |
4
| MACARTNEY LAWSON (Director) has filed a Form 4 on Viking Therapeutics, Inc.|
Txns:
| Sold 16,000 shares
@ $24, valued at
$384k
Exercised 16,000 options to buy
@ $1.19, valued at
$19k
|
|
| 05/16/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/16/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/11/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits ... |
| 05/01/2023 |
4
| Lian Brian (President & CEO) has filed a Form 4 on Viking Therapeutics, Inc.|
Txns:
| Sold 45,000 shares
@ $22.45, valued at
$1M
|
|
| 05/01/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 05/01/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/01/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 04/26/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/26/2023 |
8-K
| Quarterly results |
| 04/24/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/24/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 04/21/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/19/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 04/18/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/18/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/18/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/18/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/17/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 04/17/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 04/17/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 04/17/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 04/17/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 04/17/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 04/13/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/13/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/03/2023 |
4
| Lian Brian (President & CEO) has filed a Form 4 on Viking Therapeutics, Inc.|
Txns:
| Sold 88,000 shares
@ $16.95, valued at
$1.5M
Sold 65,382 shares
@ $17.45, valued at
$1.1M
Sold 67,970 shares
@ $17.45, valued at
$1.2M
Sold 22,000 shares
@ $17.85, valued at
$392.7k
Granted 300,000 shares
@ $0
Paid exercise price by delivering 200,000 shares
@ $17.57, valued at
$3.5M
Exercised 115,852 options to buy
@ $1.23, valued at
$142.5k
Exercised 19,530 options to buy
@ $9.49, valued at
$185.3k
Exercised 67,970 options to buy
@ $9.49, valued at
$645k
|
|
| 04/03/2023 |
4
| ZANTE GREG (CFO) has filed a Form 4 on Viking Therapeutics, Inc.|
Txns:
| Sold 131,029 shares
@ $17.0025, valued at
$2.2M
Sold 30,911 shares
@ $18, valued at
$556.4k
Granted 56,667 shares
@ $0
Paid exercise price by delivering 55,166 shares
@ $17.57, valued at
$969.3k
Exercised 32,000 options to buy
@ $8.52, valued at
$272.6k
Exercised 42,000 options to buy
@ $7.69, valued at
$323k
Exercised 12,250 options to buy
@ $4.65, valued at
$57k
Exercised 7,500 options to buy
@ $4.12, valued at
$30.9k
Exercised 30,911 options to buy
@ $7.77, valued at
$240.2k
|
|
| 04/03/2023 |
4
| Mancini Marianna (COO) has filed a Form 4 on Viking Therapeutics, Inc.|
Txns:
| Exercised 36,100 shares
@ $17.0091, valued at
$614k
Granted 56,667 shares
@ $0
Paid exercise price by delivering 30,799 shares
@ $17.57, valued at
$541.1k
Exercised 23,100 options to buy
@ $8.52, valued at
$196.8k
Exercised 10,000 options to buy
@ $7.69, valued at
$76.9k
Exercised 3,000 options to buy
@ $6.47, valued at
$19.4k
|
|
| 04/03/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Viking Therapeutics Announces Closing of Public Offering of Common Stock And Full Exercise of Underwriters’ Option to Purchase Additional Shares SAN DIEGO, CA – April 3, 2023 – Viking Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the closing of its previously announced underwritten public offering of 19,828,300 shares of its common stock at a public offering price of $14.50 per share, which includes the exercise in full by the underwriters of their option to purchase up to 2,586,300 additional shares of common stock. The gross proceeds to Viking from this offering are approximately $287.5 million, before deducting underwriting discounts and commissions and other estimated ..." |
|
|
|
|